Novo Nordisk(US:NVO) 智通财经网·2025-08-05 14:37Core Viewpoint - Novo Nordisk (NVO.US) faces a decline of over 2% in stock price to $47.64 due to a downward revision of its annual revenue and operating profit growth expectations, citing challenges in the GLP-1 market as the reason for the adjustment [1] Group 1: Legal Issues - A group of shareholders has filed a proposed class action lawsuit against Novo Nordisk in a federal court in New Jersey, seeking compensation for losses allegedly caused by securities fraud between May 7, 2025, and July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the downward revision of performance guidance led to a sharp decline in stock price, resulting in shareholder losses [1]